Lupin launches Ganirelix Acetate Injection

15 Feb 2024 Evaluate

Lupin has launched Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S. (IQVIA MAT December 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. 

Lupin Share Price

2090.15 -23.95 (-1.13%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×